EnterNext

Enterome is a clinical-stage biopharmaceutical company that leverages its proprietary bacterial mimicry platform to develop a new generation of immunomodulatory drugs. The company's technology identifies bacterial peptides that mimic human antigens, allowing for the creation of 'OncoMimics' therapeutic vaccines to trigger targeted immune responses against cancer and 'EndoMimics' bioactives to treat inflammatory diseases. Its lead oncology candidate, EO2401, is currently in Phase 1/2 clinical trials for glioblastoma and adrenal tumors, while its partnered candidate sibofimloc (TAK-018) is being evaluated in Phase 2 for Crohn's disease. Enterome has established significant strategic partnerships with major pharmaceutical companies, including Takeda and Bristol Myers Squibb, to advance its innovative pipeline.